Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | ILK | Q13418 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | NCS1 | P62166 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15708155 | 0.80 | DYRK1A (0.54) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL1913811 | 0.79 | SCN4A (0.75) | DYRK1AILKEPHX2SCN4ABACE1 | |
| SCHEMBL1748145 | 0.79 | DYRK1A (0.52) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL777758 | 0.79 | DYRK1A (0.52) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL31547354 | 0.79 | DYRK1A (0.52) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL9853857 | 0.79 | POLB (0.56) | DYRK1AILKEPHX2SCN4AALOX5 | |
| SCHEMBL30261092 | 0.79 | SCN4A (0.75) | DYRK1AILKEPHX2SCN4ABACE1 | |
| Hydrochloric Acid SCHEMBL9362913 | 0.77 | SCN4A (0.73) | DYRK1AILKEPHX2SCN4ABACE1 | |
| SCHEMBL17153983 | 0.77 | ALOX5 (0.52) | DYRK1AILKEPHX2SCN4AKDM4E | |
| SCHEMBL21652240 | 0.76 | DYRK1A (0.54) | DYRK1AILKEPHX2SCN4AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-0458549-A1 | N-alkyl-spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | DYRK1A 804/4885ILK 4302/4885EPHX2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.